These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 16406853

  • 1. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol.
    Xu D, Lu Q, Hu X.
    Cancer Lett; 2006 Nov 18; 243(2):274-80. PubMed ID: 16406853
    [Abstract] [Full Text] [Related]

  • 2. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by milbemycin compounds in adriamycin-resistant human breast carcinoma (MCF-7/adr) cells.
    Xiang W, Gao A, Liang H, Li C, Gao J, Wang Q, Shuang B, Zhang J, Yan Y, Wang X.
    Toxicol In Vitro; 2010 Sep 18; 24(6):1474-81. PubMed ID: 20656007
    [Abstract] [Full Text] [Related]

  • 3. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
    Liu H, Zang C, Emde A, Planas-Silva MD, Rosche M, Kühnl A, Schulz CO, Elstner E, Possinger K, Eucker J.
    Eur J Pharmacol; 2008 Sep 04; 591(1-3):43-51. PubMed ID: 18588872
    [Abstract] [Full Text] [Related]

  • 4. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX, Yang XH.
    Yao Xue Xue Bao; 2008 May 04; 43(5):461-6. PubMed ID: 18717331
    [Abstract] [Full Text] [Related]

  • 5. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
    Kawasaki K, Watanabe M, Sakaguchi M, Ogasawara Y, Ochiai K, Nasu Y, Doihara H, Kashiwakura Y, Huh NH, Kumon H, Date H.
    Cancer Gene Ther; 2009 Jan 04; 16(1):65-72. PubMed ID: 18654608
    [Abstract] [Full Text] [Related]

  • 6. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC, Liang YC, Klutz A, Hsu CI, Lin CF, Mold DE, Chou TC, Lee YC, Huang RC.
    Cancer Chemother Pharmacol; 2006 Nov 04; 58(5):640-53. PubMed ID: 16544145
    [Abstract] [Full Text] [Related]

  • 7. Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation.
    Shi R, Peng H, Yuan X, Zhang X, Zhang Y, Fan D, Liu X, Xiong D.
    J Cell Biochem; 2013 Aug 04; 114(8):1890-900. PubMed ID: 23494858
    [Abstract] [Full Text] [Related]

  • 8. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
    Li X, Sun B, Zhu CJ, Yuan HQ, Shi YQ, Gao J, Li SJ, Lou HX.
    Toxicol In Vitro; 2009 Feb 04; 23(1):29-36. PubMed ID: 18938236
    [Abstract] [Full Text] [Related]

  • 9. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
    Chen G, Waxman DJ.
    J Pharmacol Exp Ther; 1995 Sep 04; 274(3):1271-7. PubMed ID: 7562498
    [Abstract] [Full Text] [Related]

  • 10. Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models.
    Hou W, Chen L, Yang G, Zhou H, Jiang Q, Zhong Z, Hu J, Chen X, Wang X, Yuan Y, Tang M, Wen J, Wei Y.
    Phytother Res; 2008 Aug 04; 22(8):1125-32. PubMed ID: 18570244
    [Abstract] [Full Text] [Related]

  • 11. A novel indirubin derivative PHII-7 potentiates adriamycin cytotoxicity via inhibiting P-glycoprotein expression in human breast cancer MCF-7/ADR cells.
    Shi R, Li W, Zhang X, Zhang Y, Peng H, Xie Y, Fan D, Liu R, Liu X, Xiong D.
    Eur J Pharmacol; 2011 Nov 01; 669(1-3):38-44. PubMed ID: 21871878
    [Abstract] [Full Text] [Related]

  • 12. Reversal effects of two new milbemycin compounds on multidrug resistance in MCF-7/adr cells in vitro.
    Gao A, Liang H, Wang X, Zhang X, Jing M, Zhang J, Yan Y, Xiang W.
    Eur J Pharmacol; 2011 Jun 01; 659(2-3):108-13. PubMed ID: 21458446
    [Abstract] [Full Text] [Related]

  • 13. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells.
    Dönmez Y, Gündüz U.
    Biomed Pharmacother; 2011 Mar 01; 65(2):85-9. PubMed ID: 21237614
    [Abstract] [Full Text] [Related]

  • 14. Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells.
    Li C, Guan X, Xue H, Wang P, Wang M, Gai X.
    Pathol Res Pract; 2017 Jul 01; 213(7):848-853. PubMed ID: 28554760
    [Abstract] [Full Text] [Related]

  • 15. Modulation of P-glycoprotein expression by honokiol, magnolol and 4-O-methylhonokiol, the bioactive components of Magnolia officinalis.
    Han HK, Van Anh LT.
    Anticancer Res; 2012 Oct 01; 32(10):4445-52. PubMed ID: 23060571
    [Abstract] [Full Text] [Related]

  • 16. Novel gene P28GANK confers multidrug resistance by modulating the expression of MDR-1, Bcl-2 and Bax in osteosarcoma cells.
    Wang G, Rong J, Zhou Z, Duo J.
    Mol Biol (Mosk); 2010 Oct 01; 44(6):1010-7. PubMed ID: 21287809
    [Abstract] [Full Text] [Related]

  • 17. A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line.
    Bhat UG, Winter MA, Pearce HL, Beck WT.
    Mol Pharmacol; 1995 Oct 01; 48(4):682-9. PubMed ID: 7476894
    [Abstract] [Full Text] [Related]

  • 18. Levistolide A overcomes P-glycoprotein-mediated drug resistance in human breast carcinoma cells.
    Chen F, Wang T, Wang J, Wang ZQ, Qian M.
    Acta Pharmacol Sin; 2008 Apr 01; 29(4):458-64. PubMed ID: 18358092
    [Abstract] [Full Text] [Related]

  • 19. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
    Park SJ, Wu CH, Safa AR.
    Anticancer Res; 2004 Apr 01; 24(1):123-31. PubMed ID: 15015586
    [Abstract] [Full Text] [Related]

  • 20. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by doramectin and nemadectin.
    Gao A, Wang X, Xiang W, Liang H, Gao J, Yan Y.
    J Pharm Pharmacol; 2010 Mar 01; 62(3):393-9. PubMed ID: 20487225
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.